Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA, USA.
Nephrol Dial Transplant. 2012 Sep;27(9):3631-8. doi: 10.1093/ndt/gfs131. Epub 2012 May 2.
Whether peritoneal dialysis (PD) treatment leads to greater weight gain than with hemodialysis (HD) and if this limits access of obese end-stage renal disease patients to renal transplantation has not been examined. We undertook this study to determine the interrelationship between body size and initial dialysis modality on transplantation, mortality and weight gain.
Time to transplantation, time to death and weight gain were estimated in a 1:1 propensity score-matched cohort of incident HD and PD patients treated in facilities owned by DaVita Inc. between 1 July 2001 through 30 June 2006 followed through 30 June 2007 (4008 pairs) in four strata of body mass index (BMI) (<18.5, 18.5-24.99, 25.00-29.99 and ≥ 30 kg/m(2)).
Transplantation was significantly more likely in PD patients [adjusted hazards ratio (aHR) 1.48, 95% confidence interval (95% CI) 1.29-1.70]; the probability of receiving a kidney transplant was significantly higher in each strata of BMI >18.5 kg/m(2), including with BMI ≥ 30 kg/m(2) (aHR 1.45, 95% CI 1.11-1.89). PD patients had significantly lower all-cause mortality for patients with BMI 18.50-29.99 kg/m(2). Both these findings were confirmed on analyses of the entire unmatched incident cohort (PD 4008; HD 58 471). The effect of dialysis modality on weight gain was tested in 687 propensity score-matched pairs; the odds of >2, >5 or >10% weight gain were significantly lower in PD patients.
Treatment with PD is less likely to be associated with a significant weight gain and does not limit the access of obese patients to renal transplantation.
腹膜透析(PD)治疗是否比血液透析(HD)导致更多的体重增加,以及肥胖终末期肾病患者的这种情况是否会限制其接受肾移植,尚未得到检验。我们进行这项研究旨在确定身体大小与初始透析方式对移植、死亡率和体重增加的相互关系。
在 2001 年 7 月 1 日至 2006 年 6 月 30 日期间在 DaVita Inc 拥有的设施中接受治疗的新发病例 HD 和 PD 患者中,按照 1:1 的倾向评分匹配队列,估计移植时间、死亡时间和体重增加,直到 2007 年 6 月 30 日(4008 对)。按照身体质量指数(BMI)的四个层次(<18.5、18.5-24.99、25.00-29.99 和≥30 kg/m(2)) 进行分层。
PD 患者的移植可能性明显更高[调整后的危险比(aHR)1.48,95%置信区间(95%CI)1.29-1.70];BMI>18.5 kg/m(2)的每个层次中,包括 BMI≥30 kg/m(2)(aHR 1.45,95%CI 1.11-1.89),接受肾移植的可能性明显更高。PD 患者 BMI 为 18.50-29.99 kg/m(2)时的全因死亡率明显较低。在对整个未匹配的发病队列(PD 4008;HD 58471)的分析中,都证实了这两个发现。在 687 对倾向评分匹配的患者中,测试了透析方式对体重增加的影响;PD 患者的体重增加>2%、>5%或>10%的可能性明显较低。
PD 治疗不太可能与显著的体重增加相关,并且不会限制肥胖患者接受肾移植的机会。